Literature DB >> 29276263

Calcitonin Gene-Related Peptide Receptor Antagonists for Migraine Prophylaxis.

Scot Walker1.   

Abstract

Migraine is a common disorder affecting 12% of the U.S. POPULATION: Prophylaxis is recommended for patients who experience frequent migraines. Because current drugs used for prophylaxis are not 100% effective and cause adverse effects that affect compliance, new strategies have been studied to prevent headaches. One new pharmacologic strategy is to use an inhibitor of the calcitonin gene-related peptide (CGRP). As a class, the CGRP receptor inhibitors have reduced monthly migraine days and are well tolerated. This article will briefly review CGRP inhibitors in development.

Entities:  

Keywords:  drug information; formulary management/P&T; investigational drugs; neurology

Year:  2017        PMID: 29276263      PMCID: PMC5735702          DOI: 10.1177/0018578717723005

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  4 in total

Review 1.  Migraine--current understanding and treatment.

Authors:  Peter J Goadsby; Richard B Lipton; Michel D Ferrari
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

Review 2.  The cost of migraine and its treatment.

Authors:  Lawrence D Goldberg
Journal:  Am J Manag Care       Date:  2005-06       Impact factor: 2.229

3.  Migraine prevalence, disease burden, and the need for preventive therapy.

Authors:  R B Lipton; M E Bigal; M Diamond; F Freitag; M L Reed; W F Stewart
Journal:  Neurology       Date:  2007-01-30       Impact factor: 9.910

Review 4.  An update on migraine: current understanding and future directions.

Authors:  Francesca Puledda; Roberta Messina; Peter J Goadsby
Journal:  J Neurol       Date:  2017-03-20       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.